接受全身性癌症治療的長者出現嚴重治療相關毒性（TRT）的風險較高。現有的預測工具如 CARG 及 CRASH 在華人族群中的適用性有限，且未能全面涵蓋與較新療法（包括免疫治療及標靶治療）相關的毒性。
適應症：Cancer (Solid Tumors)、Geriatric Oncology
收案條件
納入條件
- Aged 65 or above
- A diagnosis of lung cancer, gastrointestinal cancer, breast cancer, prostate cancer, and uterine cancer with histological confirmation or radiological diagnosis\*\*
- Seen by the oncologist and scheduled to receive a new systemic anti-cancer treatment, including chemotherapy, targeted therapy, and immunotherapy, in either radical or first/second-line palliative intent. The planned treatment regimen is expected to last for at least 3 months.
- ECOG performance status of 0-2
- Agreement for treatment according to the TRTRM (ACTTOP) -risk strategy if in the TRTRM (ACTTOP) -informed care group
- Fluent in English or Chinese
- Valid consent obtained \*\* Only these five types of cancer are included to reduce the heterogeneity of the patients, as they are the top 5 cancers in Hong Kong.
排除條件
- Planned for radiotherapy alone
- Planned for systemic treatment concomitant with radiotherapy
- Scheduled to have hormonal therapy alone e.g. tamoxifen, aromatase inhibitors, luteinizing hormone-releasing hormone agonist (LHRHa)
- Planned for surgery within 3 months
- Dementia or patient mentally not fit for consent
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。